Gilead licenses HCV drugs to Indian generic makers

Gilead Sciences Inc. (NASDAQ:GILD) signed non-exclusive licensing agreements allowing seven Indian generics companies to manufacture its chronic HCV drugs sofosbuvir and sofosbuvir/ledipasvir for distribution in 91 developing countries.

Licensees will be able to set their own prices for the generics and pay a 7% royalty to Gilead. The agreements allow the generics companies to manufacture other combination therapies including sofosbuvir or ledipasvir. ...